4:21 PM
 | 
Apr 13, 2018
 |  BC Extra  |  Company News

Report: Hanmi discontinuing lung cancer drug olmutinib

Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) will discontinue development of olmutinib, which is approved in South Korea for lung cancer, the Korea Biomedical Review reported Friday. Hanmi did not...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >